Research publications

Alfred Health research outcomes are published in a wide range of peer reviewed journals. 

Search or browse research publications by year, research area, publication type or keyword.

Clear filter
Publication Details
Chronic heart failure: time to recognize this major public health problem

Krum H, Stewart S

(2006), Med J Aust, 184(4), 147-8

'Class effect' amongst cardiac drugs: term of convenience or pharmacological reality?

Krum H, Ruschitzka F

(2006), Int J Clin Pract, 60(1), 2-5

Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study

Krum H, Mohacsi P, Katus HA, Tendera M, Rouleau JL, Fowler MB, Coats AJ, Roecker EB, Packer M; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group.

(2006), Am Heart J, 151(1), 55-61

Does the presence of heart failure alter prescribing of drug therapy after myocardial infarction? A multicentre study

Krum H, Meehan A, Varigos J, Loane PR, Billah B

(2006), Med J Aust, 185(4), 191-4

Effect of angiotensin II receptor blockade on autonomic nervous system function in patients with essential hypertension

Krum H, Lambert E, Windebank E, Campbell DJ, Esler M

(2006), Am J Physiol Heart Circ Physiol, 290(4), H1706-12

Guidelines for the prevention, detection and management of people with chronic heart failure in Australia 2006

Krum H, Jelinek MV, Stewart S, Sindone A, Atherton JJ, Hawkes AL; CHF Guidelines Core Writers

(2006), Med J Aust, 185(10), 549-57

Tolerability of beta-blockers in elderly patients with chronic heart failure: the COLA II study

Krum H, Hill J, Fruhwald F, Sharpe C, Abraham G, Zhu JR, Poy C, Kragten JA

(2006), Eur J Heart Fail, 8(3), 302-7

Diuretics in the treatment of heart failure: mainstay of therapy or potential hazard?

Krum H, Cameron P

(2006), J Card Fail, 12(5), 333-5

Impact of Statin Therapy on Clinical Outcomes in Chronic Heart Failure Patients According to Beta-Blocker Use: Results of CIBIS II

Krum H, Bailey M, Meyer W, Verkenne P, Dargie H, Lechat P, Anker S

(2006), Cardiology, 108(1), 28-34

Blood pressure effects of COX-2 inhibitors

Krum H, Aw TJ, Liew D, Haas S

(2006), J Cardiovasc Pharmacol, 47 Suppl 1, S43-8

Heart Failure and Nephropathy: Catastrophic and Interrelated Complications of Diabetes

Gilbert RE, Connelly K, Kelly DJ, Pollock CA, Krum H

(2006), Clin J Am Soc Nephrol, 1(2), 193-208

Heart failure: the forgotten complication of diabetes

Gilbert R, Krum H, Parker TG

(2006), Metabolic Syndrome Rounds, 4, 128-30

Importance of renin in blood pressure regulation and therapeutic potential of renin inhibition.

Ferro A, Gilbert R, Krum H

(2006), Int J Clin Pract, 60(5), 577-81

Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence

Dulin BR, Krum H

(2006), Curr Opin Cardiol, 21(4), 393-9

Load-sensitive measures may overestimate global systolic function in the presence of left ventricular hypertrophy: a comparison with load-insensitive measures

Connelly KA, Prior DL, Kelly DJ, Feneley MP, Krum H, Gilbert RE

(2006), Am J Physiol Heart Circ Physiol, 290(4), H1699-705

Nursing sans frontieres: a three year case study of multi-state registration to support nursing practice using information technology

Clark RA, Yallop J, Wickett D, Krum H, Tonkin A, Stewart S

(2006), Aust J Adv Nurs, 24(1), 39-45

Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison

Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L; MEDAL Steering Committee

(2006), Lancet, 368(9549), 1771-81

Intra-coronary high-dose CD34+ stem cells in patients with chronic ischemic heart disease: a 12-month follow-up

Boyle AJ, Whitbourn R, Schlicht S, Krum H, Kocher A, Nandurkar H, Bergmann S,Daniell M, O'Day J, Skerrett D, Haylock D, Gilbert RE, Itescu S

(2006), Int J Cardiol, 109(1), 21-7

Can the blood pressure effects of COX-2 selective inhibitors be explained by changes in plasma aldosterone levels?

Aw TJ, Liew D, Tofler GH, Schneider HG, Morel-Kopp MC, Billah B, Krum H

(2006), J Hypertens, 24(10), 1979-84

The foundation and launch of the Melbourne Interventional Group: a collaborative interventional cardiology project

Ajani AE, Szto G, Duffy SJ, Eccleston D, Clark DJ, Lefkovits J, Chew DP, Warren R, Black A, New G, Walton A, Lew R, Shaw J, Horrigan M, Sebastian M, Yan BP, Brennan A, Meehan A, Reid C, Krum H; Melbourne Interventional Group investigators

(2006), Heart Lung Circ, 15(1), 44-7

742 743 744 745 746